Transformation method for determination results of biomarkers of urine and blood
By selecting highly related compounds in urine and blood, a simple transformation formula was established, the problem of insufficient urine correlation was solved, the accuracy of urine samples used to replace blood tests was achieved, and urine was improved in clinical testing. application potential.
Patent Information
- Application Number
- CN202411137255.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, urine is insufficiently correlated as a clinical test sample, making it difficult to replace blood samples, especially when frequent monitoring of health conditions is required, the sensitivity and non-invasive advantages of urine cannot be effectively utilized.
130 endogenous and exogenous compounds were selected, and by comparing the detection results of plasma and urine, the compounds that are highly correlated with urine and blood were selected, and a simple transformation formula was given, and their accuracy was verified using a large amount of data. To achieve the conversion of urine content measurement results into blood content. The specific steps include selecting compounds such as cortisol, cortisone and ponylosolone, performing urine samples assays and pretreatment, and using LC-MS/MS detection to establish a conversion formula for plasma compound content.
Analyze alternatives to predict the concentration of specific compounds in the blood through urine samples when blood samples cannot be obtained immediately, providing accurate qualitative and quantitative analysis, solving the transformation of high-correlation compounds between urine and blood, and improving the The application potential of urine in clinical testing.
Smart Images

Figure CN119023837A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for converting the results of biomarker determination in urine and blood. Background Art
[0002] The use of urine as a biological matrix to replace blood, the most commonly used biological matrix in clinical testing, has both advantages and challenges. The main advantages of using urine as a sample for clinical testing include: 1) Non-invasive sampling: Urine collection is more convenient and non-invasive than blood collection, which reduces the pain and discomfort of patients and reduces the risk of infection. 2) Easy to collect and store: Urine collection does not require professional medical personnel, patients can do it at home, and urine samples are relatively simple to store and transport. 3) Early diagnosis and monitoring: Urine contains many metabolites, hormones, toxins and other biomarkers, which can provide important information about the health of the body and help diagnose and monitor early diseases. 4) Low cost: Urine testing is usually less expensive than blood testing because its collection and processing procedures are relatively simple.
[0003] The reason why urine samples have not been used for clinical testing on a large scale is that in routine analysis, the clinical relevance of urine samples has become the biggest bottleneck problem for using urine samples instead of blood samples. In the past history of testing, blood was used as the target sample for testing in most cases, because blood is a liquid inside the human body and is directly involved in various functions of the body. Therefore, the use of internal body fluids, namely blood, can theoretically more directly and stably reflect the condition of the body. However, with the development of technology and economy, the health of the body will need to be monitored more frequently in the future, rather than the current situation, that is, when people are sick or have annual physical examinations, they will come to medical institutions for centralized blood draws and tests. This situation will change in the near future, and non-invasive sampling and sampling that reduces the constraints of time, location and auxiliary personnel will be increasingly needed by society. As one of the most sensitive biological matrices, urine has the advantages that make it the most potential biological sample to meet this demand in the future.
[0004] The present invention aims to select suitable compounds that can be highly correlated in urine and blood, and establish a simple calculation method rather than a complex algorithm or a black box machine learning evaluation method (because these complex methods cannot be conveniently used in the interpretation and evaluation of clinical test results), so that the urine content measurement results can be converted into blood content. Summary of the invention
[0005] The purpose of the present invention is to provide a method for converting the biomarker measurement results of urine and blood; the present invention selects 130 endogenous and exogenous compounds, selects compounds with high correlation between urine and blood by comparing the test results of plasma and urine, and provides a simple conversion formula for urine and plasma. Its accuracy is evaluated through a large amount of data, making technical preparations for replacing blood with urine in future clinical tests.
[0006] The objective of the present invention is achieved through the following technical solutions:
[0007] The present invention provides a method for converting the results of biomarker determination in urine and blood, the method comprising the following steps:
[0008] S1. Select compounds with high correlation in urine and blood; the compounds are cortisol, cortisone and prednisolone;
[0009] S2. Determination of the content of cortisol, 11-deoxycortisol, cortisone and prednisolone in a urine sample of a natural person;
[0010] S3. Calculate the content of cortisol, cortisone and prednisolone in the blood sample of the natural person according to the following formula:
[0011] A. Plasma cortisol (Cortisol):
[0012] Plasma_Cortisol=147.53-41.04×(Urine_11-Deoxycortisol-2832.23) / 21799.10-72.56×(Urine _Cortisol-1521.52) / 2443.06+66.93×(Urine_Cortisone-2988.55) / 6445.89+63.80×(Urine_Pred nisolone-7810.94) / 12827.50;
[0013] B. Plasma cortisone:
[0014] Plasma_Cortisone=31.08+5.86×(Urine_11-Deoxycortisol-2832.23) / 21799.10-6.00×(Urine_C ortisol-1521.52) / 2443.06-3.93×(Urine_Cortisone-2988.55) / 6445.89+4.21×(Urine_Prednis olone-7810.94) / 12827.50;
[0015] C. Plasma Prednisolone:
[0016] Plasma_Prednisolone=4.75-1.35×(Urine_11-Deoxycortisol-2832.23) / 21799.10-1.03×(Urine _Cortisol-1521.52) / 2443.06+1.80×(Urine_Cortisone-2988.55) / 6445.89+0.71×(Urine_Predni solo-7810.94) / 12827.50.
[0017] As an embodiment of the present invention, in step S2, the pre-treatment of the urine sample before the measurement comprises the following steps:
[0018] S2-1, adding glucuronidase solution to the urine sample, and performing enzymolysis at 25-50° C. for 1-5 hours;
[0019] S2-2, urine after enzymatic hydrolysis is subjected to solid phase extraction and eluted;
[0020] S2-3. Dilute the eluate with water and perform the test.
[0021] As an embodiment of the present invention, the concentration of the glucuronidase solution in step S2-1 is 2000-5,000 U / mL, and the volume ratio of the glucuronidase solution to the sample solution is 10:1-40:1.
[0022] As an embodiment of the present invention, step S2-2 is specifically as follows: the solid phase extraction is to load the enzymatically hydrolyzed urine onto an HLB solid phase extraction plate and a MAX solid phase extraction plate, respectively, add water for rinsing, and then elute with an eluent.
[0023] As an embodiment of the present invention, the eluent is a mixed solution comprising formic acid and an organic phase, wherein the mass fraction of formic acid in the mixed solution is 0.5-5%; the organic phase comprises acetonitrile and methanol, and the volume ratio of the two is 9:1-8:2. In some specific implementation examples, the mass fraction of formic acid in the mixed solution is 2%; the organic phase comprises acetonitrile and methanol, and the volume ratio of the two is 8:2.
[0024] As an embodiment of the present invention, in step S2-3, the eluent is diluted with 1-2 times water, vortexed and then detected.
[0025] As an embodiment of the present invention, the detection is LC-MS / MS detection.
[0026] As an embodiment of the present invention, the liquid phase conditions used for the detection are:
[0027] Column: ACQUITY UPLC BEH Phenyl
[0028] Mobile phase A: 0.1% ammonium fluoride in formic acid, pH 2.5-4.5;
[0029] Mobile phase B: acetonitrile:methanol volume ratio 9:1;
[0030] The mobile phase gradient conditions were:
[0031] Time (min) Flow rate (mL / min) Mobile phase A Mobile phase B 0.00 0.40 75% 25% 0.20 0.40 75% 25% 8.00 0.40 5% 95% 9.00 0.40 5% 95% 9.01 0.40 75% 25% 11.00 0.40 75% 25% .
[0032] As an embodiment of the present invention, the mass spectrometry analysis conditions used for the detection are:
[0033] Ion source: ESI ion source
[0034] Detection mode: MRM acquisition mode;
[0035] The ion source parameters are: cone voltage: 30 V; ion source temperature: 150 °C; desolvation temperature: 500 °C;
[0036] MRM monitoring information is:
[0037] Serial number Compound Name Precursor ion mass-to-charge ratio Product ion mass-to-charge ratio Cone voltage / V Collision voltage / V 01 Prednisolone 361.1 343.7 20 30 02 11-Deoxycortisol 347.2 97.7 20 20 03 Cortisol 363.2 122 20 20 04 Cortisone 361.2 121.7 20 22
[0038] Compared with the prior art, the present invention has the following beneficial effects:
[0039] 1) The present invention has found compounds with high correlation in blood and urine through experience and a large number of calculations among 130 typical endogenous and exogenous compounds, which are cortisol, cortisone and prednisolone; in the specific implementation process, all 130 compounds have their own standard products, which can accurately determine what specific compound the compound is, not the result guessed by mass spectrometry information, but the qualitative result accurately determined. Further, 130 compounds in blood and urine are absolutely quantified using their standard products, ensuring accurate quantitative results. Under this premise, three highly correlated indicators in blood and urine are confirmed by detailed calculations. In the method, standard products are used to perform qualitative and quantitative analysis on 130 compounds, and three indicators that can be converted in urine and blood are confirmed through highly correlated calculations and screening, namely cortisol, cortisone and prednisolone. This method has not been reported.
[0040] 2) The present invention uses urine sample data and a simplified linear formula to predict the concentration of a specific compound in a patient's blood. This method provides an alternative when a blood sample cannot be obtained immediately, and is particularly suitable for predicting the concentration of cortisol, cortisone, and prednisolone. A specific equation is given and verified, and the equation has never been reported before.
[0041] 3) In the conversion formula of the present invention, the contents of four compounds, namely Cortisol (Cortisol concentration in urine), Cortisone (Cortisone concentration in urine), 11-deoxycortisol (11-Deoxycortisol concentration in urine), and Prednisolone (Prednisolone concentration in urine) are used to calculate the contents of three compounds in blood, namely Cortisol (Cortisol concentration in blood), Cortisone (Cortisone concentration in blood), and Prednisolone (Prednisolone concentration in blood). This calculation method of calculating the contents of three compounds in blood using the contents of four compounds in urine has never been reported.
[0042] 4) Compared with similar prior patents such as CN 114402202 A “Method for associating biomarkers in non-blood body fluids with biomarkers in blood”, the prior patent proposed possible algorithms for associating the measurement results of non-blood samples with the measurement results of blood samples. These algorithms are very general. First of all, the patent does not know which compounds in non-blood samples may have a high correlation with the compounds in blood samples. It should be explained that because the functions and environments of the compounds in blood and urine are very different, the compounds in urine are usually excreted from the body, which belongs to the excretion form, while some of the compounds in blood are mainly in functional or active forms, and some are in metabolic forms. Therefore, the compounds in blood and urine are very different, and most of them are not related. In addition, the matrix of blood and urine is very different. There is a large amount of protein in blood, while there is almost no protein in urine or the content is very low. The huge difference in matrix causes that even if it is the same compound, the amount shown in blood and urine is affected by the matrix environment, and the reading directly measured is also very different. In this case, it is very important to find highly correlated compounds in blood and urine. This correlation is not necessarily linear, but this high correlation is the key prerequisite for the conversion of blood and urine compounds. If this problem is not solved first, it will fall into the trap of covering one's ears and stealing the bell. Under the premise of finding and understanding highly correlated compounds in blood and urine, a conversion formula for the blood and urine content of a specific compound must be established. This formula is not like CN 114402202 A, which just makes a ratio and puts this ratio into it, but how to know that the ratio of the content of the target compound in the non-blood matrix to the content in the blood is a constant? This is completely without basis and completely impossible. Therefore, the ideas and problems solved by CN 114402202A and the present invention are completely different. The core difference is that the present invention uses real data to specifically search for compounds that are highly correlated in blood and urine, while CN114402202 A assumes that all at least multiple compounds are highly correlated in blood and non-blood, which is completely without basis and data. Furthermore, the present invention uses real data to calculate and simulate specific formulas to calculate the content conversion of compounds in urine and compounds in blood. These formulas are obtained through real data, multiple experiments and a large number of calculations, which are completely different from the ideas and problem-solving methods of CN 114402202A. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0044] Figure 1To find highly correlated compounds among the specific 130 typical compounds and provide a specific calculation formula schematic diagram. DETAILED DESCRIPTION
[0045] The present invention is further illustrated by the following examples, but any example or combination thereof should not be construed as limiting the scope or implementation of the present invention. Without departing from the spirit and scope of the present invention, those skilled in the art may make any modifications or changes to the technical solution of the present invention, and such modifications and changes are also included in the scope of the present invention.
[0046] In the examples, if the specific conditions are not specified, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can be implemented equally without certain specific details. In other embodiments, methods, means, equipment and steps well known to those skilled in the art are not described in detail to highlight the gist of the present invention.
[0047] The present invention selected 130 endogenous and exogenous compounds, compared the test results of plasma and urine, selected compounds with high correlation between urine and blood, and provided a simple conversion formula between urine and plasma, and evaluated the accuracy, making technical preparations for the future clinical testing to replace blood with urine. The specific steps are as follows:
[0048] 1) Blood and urine samples were collected from 61 natural persons at the same time, and 130 typical endogenous and exogenous compounds were detected in the blood and urine samples, respectively, to obtain a 130×61 data matrix;
[0049] 2) Among 130 typical endogenous and exogenous compounds, based on experience and a large number of calculations, three highly correlated compounds were found, namely cortisol, cortisone and prednisolone;
[0050] 3) On the premise of finding highly correlated compounds, a calculation formula is established to estimate the compound content in urine and calculate the compound content in blood. The detailed formula is as follows:
[0051] A. Plasma cortisol (Cortisol):
[0052] Plasma_Cortisol=147.53-41.04×(Urine_11-Deoxycortisol-2832.23) / 21799.10-72.56×(Urine _Cortisol-1521.52) / 2443.06+66.93×(Urine_Cortisone-2988.55) / 6445.89+63.80×(Urine_Pred nisolone-7810.94) / 12827.50;
[0053] B. Plasma cortisone:
[0054] Plasma_Cortisone=31.08+5.86×(Urine_11-Deoxycortisol-2832.23) / 21799.10-6.00×(Urine_C ortisol-1521.52) / 2443.06-3.93×(Urine_Cortisone-2988.55) / 6445.89+4.21×(Urine_Prednis olone-7810.94) / 12827.50;
[0055] C. Plasma Prednisolone:
[0056] Plasma_Prednisolone=4.75-1.35×(Urine_11-Deoxycortisol-2832.23) / 21799.10-1.03×(Urine _Cortisol-1521.52) / 2443.06+1.80×(Urine_Cortisone-2988.55) / 6445.89+0.71×(Urine_Predni solo-7810.94) / 12827.50;
[0057] By using the above formula, the content of the compound in the urine can be used to accurately predict the content of the compound in the blood sample. See the following test examples and embodiments for details.
[0058] Test Example 1
[0059] 61 healthy people were selected, and urine and blood samples were collected one by one according to the standard sampling process. A total of 130 typical exogenous and endogenous compounds in the urine and blood of the 61 healthy people were accurately determined. The specific operation steps are as follows:
[0060] Step 1: Measure the concentration of compounds in urine
[0061] 1) Collect urine sample
[0062] Collect a urine sample from the patient using a standard urine collection container.
[0063] 2) Laboratory testing
[0064] The urine samples were sent to a clinical laboratory and the concentrations of the following compounds were measured by chromatography-mass spectrometry (LC-MS / MS) (the remaining conditions were the same as in Example 1, and the mass spectrometry conditions were as follows):
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078] 3) Record the concentration value
[0079] Record the concentration values measured in the laboratory for subsequent calculations.
[0080] Step 2: Collect blood samples
[0081] The blood samples were sent to a clinical laboratory, and the concentrations of the following compounds were measured by chromatography-mass spectrometry (LC-MS / MS) (the remaining conditions were the same as in Example 1, and the mass spectrometry conditions were as follows):
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096] Record the concentration values measured in the laboratory.
[0097] Step 3: The test results of 130 compounds and 61 individuals in blood and urine formed a normalized data matrix of 130×61×2:
[0098] Through comprehensive evaluation, it was found that among these 130 typical exogenous and endogenous compounds, the contents between urine and blood were highly correlated, namely, the representative compounds were: cortisol, cortisone, and prednisolone.
[0099] Step 5: Based on the highly correlated compounds, an evaluation method suitable for clinical use was established.
[0100] A linear formula was established to simplify data conversion. The conversion formulas for the contents of various compounds in blood and urine were obtained; the specific conversion formulas are:
[0101] A. Plasma cortisol (Cortisol):
[0102] Plasma_Cortisol=147.53-41.04×(Urine_11-Deoxycortisol-2832.23) / 21799.10-72.56×(Urine _Cortisol-1521.52) / 2443.06+66.93×(Urine_Cortisone-2988.55) / 6445.89+63.80×(Urine_Pred nisolone-7810.94) / 12827.50
[0103] B. Plasma cortisone:
[0104] Plasma_Cortisone=31.08+5.86×(Urine_11-Deoxycortisol-2832.23) / 21799.10-6.00×(Urine_C ortisol-1521.52) / 2443.06-3.93×(Urine_Cortisone-2988.55) / 6445.89+4.21×(Urine_Prednis olone-7810.94) / 12827.50
[0105] C. Plasma Prednisolone:
[0106] Plasma_Prednisolone=4.75-1.35×(Urine_11-Deoxycortisol-2832.23) / 21799.10-1.03×(Urine _Cortisol-1521.52) / 2443.06+1.80×(Urine_Cortisone-2988.55) / 6445.89+0.71×(Urine_Predni solo-7810.94) / 12827.50.
[0107] Example 1
[0108] Step 1, select 10 people, collect urine and blood samples at the same time period, and use chromatography-mass spectrometry (LC-MS / MS) to determine the content of the following 4 compounds, Cortisol, Cortisone, 11-deoxycortisol, Prednisolone;
[0109] A. Sample pretreatment method:
[0110] 1) Take 200 μL of urine and plasma samples from each sample;
[0111] 2) Add glucuronidase solution to convert the metabolites of hormones, bisphenol A and plasticizers in urine into the prototype of hormones, the prototype of bisphenol A and the primary metabolites of plasticizers; perform enzymatic hydrolysis at 35°C for 1 hour to cut the chemical bonds of the bound metabolites;
[0112] in:
[0113] The concentration of the glucuronidase solution was 5,000 U / mL;
[0114] The volume ratio of the glucuronidase solution to the sample solution was 40:1.
[0115] 3) The enzymatically hydrolyzed urine was loaded onto an HLB solid phase extraction plate and a MAX solid phase extraction plate, with 250 μL loaded onto each plate; water was added for elution and then eluted with an eluent, the eluent being a mixed solution containing formic acid and an organic phase, the mass fraction of formic acid in the mixed solution being 2%; the organic phase included acetonitrile and methanol, and the volume ratio of the two was 8:2.
[0116] 4) The eluates from the HLB solid phase extraction plate and the MAX solid phase extraction plate were combined and collected in step 4), 50 μL of the eluate was added to 100 μL of water for dilution; after vortex mixing, the mixture was injected into the UPLC / MS mass spectrometer for detection and analysis.
[0117] B. Liquid phase conditions and mass spectrometry conditions are as follows:
[0118] Column: ACQUITY UPLC BEH Phenyl
[0119] Mobile phase A: 0.1% ammonium fluoride in formic acid, pH 2.5-4.5;
[0120] Mobile phase B: acetonitrile:methanol volume ratio 9:1;
[0121] The mobile phase gradient conditions were:
[0122] Time (min) Flow rate (mL / min) Mobile phase A Mobile phase B 0.00 0.40 75% 25% 0.20 0.40 75% 25% 8.00 0.40 5% 95% 9.00 0.40 5% 95% 9.01 0.40 75% 25% 11.00 0.40 75% 25%
[0123] C. Mass spectrometry analysis conditions:
[0124] Ion source: ESI ion source
[0125] Detection mode: MRM acquisition mode;
[0126] The ion source parameters are: cone voltage: 30 V; ion source temperature: 150 °C; desolvation temperature: 500 °C;
[0127] MRM monitoring information is:
[0128] Serial number Compound Name Precursor ion mass-to-charge ratio Product ion mass-to-charge ratio Cone voltage / V Collision voltage / V 01 Prednisolone 361.1 343.7 20 30 02 11-Deoxycortisol 347.2 97.7 20 20 03 Cortisol 363.2 122 20 20 04 Cortisone 361.2 121.7 20 22
[0129] D. The results are as follows:
[0130]
[0131]
[0132] The units of the measured and calculated values of the corresponding compound contents in plasma and urine are ng / mL.
[0133] Step 2:
[0134] Based on the concentration of the compound in urine, the concentration of the compound in blood is predicted using the following formula:
[0135] A. Plasma cortisol (Cortisol):
[0136] Plasma_Cortisol=147.53-41.04×(Urine_11-Deoxycortisol-2832.23) / 21799.10-72.56×(Urine _Cortisol-1521.52) / 2443.06+66.93×(Urine_Cortisone-2988.55) / 6445.89+63.80×(Urine_Pred nisolone-7810.94) / 12827.50;
[0137] B. Plasma cortisone:
[0138] Plasma_Cortisone=31.08+5.86×(Urine_11-Deoxycortisol-2832.23) / 21799.10-6.00×(Urine_C ortisol-1521.52) / 2443.06-3.93×(Urine_Cortisone-2988.55) / 6445.89+4.21×(Urine_Prednis olone-7810.94) / 12827.50;
[0139] C. Plasma Prednisolone:
[0140] Plasma_Prednisolone=4.75-1.35×(Urine_11-Deoxycortisol-2832.23) / 21799.10-1.03×(Urine _Cortisol-1521.52) / 2443.06+1.80×(Urine_Cortisone-2988.55) / 6445.89+0.71×(Urine_Predni solo-7810.94) / 12827.50.
[0141] Content measurement unit: ng / mL
[0142] Deviation CV% = (calculated value in plasma - measured value in plasma) / measured value in plasma.
[0143] The difference between the compound content in plasma calculated from the urine content and the actual measured value of the compound content in plasma is compared.
[0144]
[0145]
[0146] The compound content in plasma (ng / mL) is predicted using the formula in step 2, and the CV% reflects the difference between the compound content in plasma calculated from the urine content (predicted value) and the actual measured value of the compound content in plasma.
[0147] It can be seen from the results that the content of the compound in plasma is calculated by the content in urine, and the deviations from the actual measured values of the compound in plasma are all controlled within 30%. In the scenario where only urine samples need to be inferred from blood samples, this invention does not use machine learning (currently there are various problems and clinical promotion is difficult). It only uses formulas to calculate the content in plasma through the established equation through the content in urine, which can accurately represent the trend to the greatest extent. This result can play a good role in clinical diagnosis, solve the bottleneck problem of urine as an alternative test biological matrix, and will promote the use of urine instead of blood to evaluate health status.
[0148] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art may make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.
Claims
1. A method for converting the results of biomarker determination in urine and blood, It is characterized in that The method comprises the following steps: S1. Select compounds with high correlation in urine and blood; the compounds include cortisol, cortisone and prednisolone; S2. Determination of the content of cortisol, 11-deoxycortisol, cortisone and prednisolone in a urine sample of a natural person; S3. Calculate the content of cortisol, cortisone and prednisolone in the blood sample of the natural person according to the following formula: A. Plasma cortisol (Cortisol): Plasma cortisol = 147.53-41.04×(urine 11-deoxycortisol-2832.23) / 21799.10-72.56×(urine cortisol-1521.52) / 2443.06+66.93×(urine corticosterone-2988.55) / 6445.89+63.80×(urine prednisolone-7810.94) / 12827.50; B. Plasma cortisone: Plasma cortisone = 31.08 + 5.86 × (urine 11-deoxycortisol - 2832.23) / 21799.10 - 6.00 × (urine cortisol - 1521.52) / 2443.06 - 3.93 × (urine corticosterone - 2988.55) / 6445.89 + 4.21 × (urine prednisolone - 7810.94) / 12827.50; C. Plasma prednisolone: Plasma prednisolone = 4.75-1.35×(urinary 11-deoxycortisol-2832.23) / 21799.10-1.03×(urinary cortisol-1521.52) / 2443.06+1.80×(urinary corticosterone-2988.55) / 6445.89+0.71×(urinary prednisolone-7810.94) / 12827.
50.
2. The method for converting the results of biomarker determination in urine and blood according to claim 1, It is characterized in that In step S2, the pre-treatment of the urine sample before the measurement includes the following steps: S2-1, adding glucuronidase solution to the urine sample, and performing enzymolysis at 25-50° C. for 1-5 hours; S2-2, urine after enzymatic hydrolysis is subjected to solid phase extraction and eluted; S2-3. Dilute the eluate with water and perform the test.
3. The method for converting the results of biomarker determination in urine and blood according to claim 2, It is characterized in that The concentration of the glucuronidase solution in step S2-1 is 2000-5,000 U / mL, and the volume ratio of the glucuronidase solution to the sample solution is 10:1-40:
1.
4. The method for converting the results of biomarker determination in urine and blood according to claim 2, It is characterized in that Step S2-2 is specifically as follows: the solid phase extraction is to load the enzymatically hydrolyzed urine onto an HLB solid phase extraction plate and a MAX solid phase extraction plate respectively, add water for rinsing, and then elute with an eluent.
5. The method for converting the results of biomarker determination in urine and blood according to claim 2 or 4, It is characterized in that The eluent is a mixed solution containing formic acid and an organic phase, wherein the mass fraction of formic acid in the mixed solution is 0.5-5%; the organic phase comprises acetonitrile and methanol, and the volume ratio of the two is 9:1-8:
2.
6. The method for converting the results of biomarker determination in urine and blood according to claim 2, It is characterized in that In step S2-3, the eluate is diluted with 1-2 times water, vortexed and then tested.
7. The method for converting the results of biomarker determination in urine and blood according to claim 1, It is characterized in that The detection is LC-MS / MS detection.
8. The method for converting the results of biomarker determination in urine and blood according to claim 7, It is characterized in that The liquid phase conditions used for the detection are: Column: ACQUITY UPLC BEH Phenyl Mobile phase A: 0.1% ammonium fluoride in formic acid, pH 2.5-4.5; Mobile phase B: acetonitrile:methanol volume ratio 9:1; The mobile phase gradient conditions were: 。 9. The method for converting the results of biomarker determination in urine and blood according to claim 7, It is characterized in that The mass spectrometry analysis conditions used in the detection are: Ion source: ESI ion source Detection mode: MRM acquisition mode; The ion source parameters are: cone voltage: 30 V; ion source temperature: 150 °C; desolvation temperature: 500 °C; MRM monitoring information is: 。
